Initial clinical trial data highlight the potential for a new approach to cancer vaccines to treat patients with a wide range of KRAS mutations, Elicio Therapeutics CEO Robert Connelly explains. In this episode of the Vanguards of Health Care podcast, Connelly joins Bloomberg Intelligence biotech analyst Marc Engelsgjerd for a discussion of Elicio’s novel, lymph node-targeting vaccine platform, the company’s recent transition to the public markets via a reverse merger and the biotech scene in Boston’s booming Seaport district, where Elicio is based.  

<p>Initial clinical trial data highlight the potential for a new approach to cancer vaccines to treat patients with a wide range of KRAS mutations, Elicio Therapeutics CEO Robert Connelly explains. In this episode of the Vanguards of Health Care podcast, Connelly joins Bloomberg Intelligence biotech analyst Marc Engelsgjerd for a discussion of Elicio’s novel, lymph node-targeting vaccine platform, the company’s recent transition to the public markets via a reverse merger and the biotech scene in Boston’s booming Seaport district, where Elicio is based.  </p>

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

<p>Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.</p>

Vanguards of Health Care by Bloomberg Intelligence

Elicio’s Broad Cancer-Vaccine Ambitions

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/7a58ee84-0073-43a6-8396-b05f013ec075/transcript

Advertisement